These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 15001195)

  • 21. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group.
    Fontbonne A; Charles MA; Juhan-Vague I; Bard JM; André P; Isnard F; Cohen JM; Grandmottet P; Vague P; Safar ME; Eschwège E
    Diabetes Care; 1996 Sep; 19(9):920-6. PubMed ID: 8875083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin.
    Berne C;
    Diabet Med; 2005 May; 22(5):612-8. PubMed ID: 15842517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production.
    Perriello G; Misericordia P; Volpi E; Santucci A; Santucci C; Ferrannini E; Ventura MM; Santeusanio F; Brunetti P; Bolli GB
    Diabetes; 1994 Jul; 43(7):920-8. PubMed ID: 8013758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of insulin on the cardiac autonomic nervous system in insulin-resistant states.
    Paolisso G; Manzella D; Rizzo MR; Barbieri M; Varricchio G; Gambardella A; Varricchio M
    Clin Sci (Lond); 2000 Feb; 98(2):129-36. PubMed ID: 10657266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beneficial effects of metformin in normoglycemic morbidly obese adolescents.
    Kay JP; Alemzadeh R; Langley G; D'Angelo L; Smith P; Holshouser S
    Metabolism; 2001 Dec; 50(12):1457-61. PubMed ID: 11735093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Obese patients with type 2 diabetes poorly controlled by insulin and metformin: effects of adjunctive dexfenfluramine therapy on glycaemic control.
    Willey KA; Molyneaux LM; Yue DK
    Diabet Med; 1994; 11(7):701-4. PubMed ID: 7955998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic administration of pharmacologic doses of vitamin E improves the cardiac autonomic nervous system in patients with type 2 diabetes.
    Manzella D; Barbieri M; Ragno E; Paolisso G
    Am J Clin Nutr; 2001 Jun; 73(6):1052-7. PubMed ID: 11382659
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.
    Derosa G; Mereu R; D'Angelo A; Salvadeo SA; Ferrari I; Fogari E; Gravina A; Palumbo I; Maffioli P; Randazzo S; Cicero AF
    J Clin Pharm Ther; 2010 Oct; 35(5):565-79. PubMed ID: 20831680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.
    Kumar S; Boulton AJ; Beck-Nielsen H; Berthezene F; Muggeo M; Persson B; Spinas GA; Donoghue S; Lettis S; Stewart-Long P
    Diabetologia; 1996 Jun; 39(6):701-9. PubMed ID: 8781766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects.
    Halberstam M; Cohen N; Shlimovich P; Rossetti L; Shamoon H
    Diabetes; 1996 May; 45(5):659-66. PubMed ID: 8621019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metformin may adversely affect orthostatic blood pressure recovery in patients with type 2 diabetes: substudy from the placebo-controlled Copenhagen Insulin and Metformin Therapy (CIMT) trial.
    Hansen CS; Lundby-Christiansen L; Tarnow L; Gluud C; Hedetoft C; Thorsteinsson B; Hemmingsen B; Wiinberg N; Sneppen SB; Lund SS; Krarup T; Madsbad S; Almdal T; Carstensen B; Jørgensen ME;
    Cardiovasc Diabetol; 2020 Sep; 19(1):150. PubMed ID: 32979921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improved glycemic control increases fasting plasma acylation-stimulating protein and decreases leptin concentrations in type II diabetic subjects.
    Ozata M; Gungor D; Turan M; Ozisik G; Bingol N; Ozgurtas T; Ozdemir IC
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3659-64. PubMed ID: 11502793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adding metformin versus insulin dose increase in insulin-treated but poorly controlled Type 2 diabetes mellitus: an open-label randomized trial.
    Relimpio F; Pumar A; Losada F; Mangas MA; Acosta D; Astorga R
    Diabet Med; 1998 Dec; 15(12):997-1002. PubMed ID: 9868971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes.
    Mori Y; Itoh Y; Obata T; Tajima N
    Endocrine; 2006 Feb; 29(1):143-8. PubMed ID: 16622303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin.
    Miles JM; Leiter L; Hollander P; Wadden T; Anderson JW; Doyle M; Foreyt J; Aronne L; Klein S
    Diabetes Care; 2002 Jul; 25(7):1123-8. PubMed ID: 12087008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
    Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
    J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study.
    Lim S; An JH; Shin H; Khang AR; Lee Y; Ahn HY; Yoon JW; Kang SM; Choi SH; Cho YM; Park KS; Jang HC
    Clin Endocrinol (Oxf); 2012 Aug; 77(2):215-23. PubMed ID: 21955147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial.
    Na LX; Li Y; Pan HZ; Zhou XL; Sun DJ; Meng M; Li XX; Sun CH
    Mol Nutr Food Res; 2013 Sep; 57(9):1569-77. PubMed ID: 22930403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin.
    Derosa G; Fogari E; Cicero AF; D'Angelo A; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Gravina A; Ferrari I; Fogari R
    Hypertens Res; 2007 May; 30(5):387-94. PubMed ID: 17587750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.